10 patents
Utility
Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions
21 Feb 23
Methods for the therapeutic use of competitive inhibitors of the CCR5/CCL5 axis that express antagonist activity for RANTES (CCL5) for immunomodulatory treatment of subjects in need thereof.
Denis R. Burger
Filed: 23 Jun 16
Utility
Concentrated protein formulations and uses thereof
7 Feb 23
Described are low viscosity, hypotonic formulations containing one or more proteins, e.g., antibodies, at high concentration, uses of the formulations, and articles of manufacture.
Tracy T. Chen
Filed: 19 Mar 18
Utility
Methods for Treating or Preventing Cancers Involving the Administration of ANTI-CCR5 Receptor Agents
22 Sep 22
The present disclosure relates to the use of competitive inhibitors of the CCR5 receptor, such as the monoclonal antibody leronlimab, or binding fragments thereof, in the treatment or prevention of cancer.
Denis BURGER, Scott KELLY
Filed: 31 Jul 20
Utility
ANTI-CCR5 Agents and Methods of Treatment That Block Cancer Metastasis or Enhance Cell Death Induced by Dna Damaging Chemotherapy
26 May 22
The present disclosure relates to the use of DNA damaging agents and leronlimab (PRO 140), or other anti-CCR5 agents, to treat or prevent cancer metastases and enhance the cell killing ability of the DNA damaging agents by selectively targeting the CCR5 receptor.
Scott KELLY, Richard G. Pestell
Filed: 1 Apr 20
Utility
CCR5 Binding Agent for the Treatment of CCR5 Positive Metastatic Cancer
15 Jul 21
The present disclosure relates to the use of CCR5 binding agents, such as the leronlimab, in the treatment or prevention of CCR5+ metastatic cancer.
Scott Kelly
Filed: 13 Jan 21
Utility
Methods of treating coronavirus infection
29 Jun 21
Provided herein are methods of preventing and treating viral infections (e.g., coronavirus infection) using a CCR5 binding agent.
Scott Kelly, Nader Pourhassan, Bruce K. Patterson, Jacob B. Lalezari
Filed: 15 Jun 20
Utility
Substitution Monotherapy Treatment for HIV-1 Infection Employing Antibody PRO140
9 Dec 20
This invention relates to the use of antibody therapy as a treatment substitute, or for treatment interruption, to treat HIV-1 infected patients.
Robert T. Schooley, Nader Z. Pourhassen
Filed: 7 Jan 20
Utility
Methods for Reducing Viral Load In HIV-1 Infected Patients
30 Sep 20
This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log10 to 2.5 log10 at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log10 at about nine days following administration of the CCR5 receptor antagonist.
William C. Olson, Paul J. Maddon, Daniel C. Pevear, Robert J. Israel, Jose D. Murga
Filed: 31 Oct 19
Utility
Substitution monotherapy treatment for HIV-1 infection employing antibody PRO140
17 Feb 20
This invention relates to the use of antibody therapy as a treatment substitute, or for treatment interruption, to treat HIV-1 infected patients.
Robert T. Schooley, Nader Z. Pourhassen
Filed: 19 Aug 15
Utility
Methods for reducing viral load in HIV-1 infected patients
9 Dec 19
This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log10 to 2.5 log10 at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log10 at about nine days following administration of the CCR5 receptor antagonist.
William C. Olson, Paul J. Maddon, Daniel C. Pevear, Robert J. Israel, Jose D. Murga
Filed: 16 Sep 12
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first